Piper Jaffray analyst Christopher Raymond keeps a Neutral rating on Amag Pharmaceuticals following this morning's announcement that the company will acquire Perosphere Pharmaceuticals and global rights to its anticoagulant reversal agent, ciraparantag. The acquisition seems to be a good strategic fit with Feraheme, though whether the profile is sufficiently differentiated to drive adoption over other novel oral anticoagulant reversal agents "remains to be seen," Raymond tells investors in a research note. The analyst thinks a deal outside of women's health is a good move for Amag, but he continues to have concerns on Makena, Intrarosa and the rest of the company's women's health portfolio.